Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 19/20 | 0.49 |
| ▸ | TCF7L2 | Q9NQB0 | 19/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016359 | 0.93 | HRH4 (0.47) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7019931 | 0.91 | CTNNB1 (0.49) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7021735 | 0.90 | HRH4 (0.47) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7017050 | 0.90 | HRH4 (0.50) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL8179499 | 0.89 | CTNNB1 (0.50) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7011197 | 0.89 | PDE4A (0.43) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7014271 | 0.88 | APP (0.42) | HRH4 | |
| SCHEMBL7012148 | 0.88 | CTNNB1 (0.48) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL7019721 | 0.87 | PDE4A (0.50) | CTNNB1TCF7L2 | |
| SCHEMBL7013552 | 0.87 | PDE4A (0.56) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934321-B1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2003-08-06 | — | — | EP | disclosed |
| EP-0934321-A1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GmbH (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017668-A1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 1998-04-30 | — | — | WO | disclosed |